Randomized , double blind, placebo controlled parallel study (Koh et al., 2008Koh KK, Quon MJ, Han SH, Lee Y, Ahn JY, Kim SJ, et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care. 2008;31(4):776-782.) |
Korea |
Hypercholesterolemia |
156 |
2 months |
Each 32 patients given either placebo, SIM 10, 20, 40 or 80 mg/day |
Not measured |
SIM 80 mg/day increase glucose level |
SIM 10, 20, 40 and 80 mg/day increase insulin level |
SIM 10,20, 40 and 80 mg/day reduce insulin sensitivity |
SIM 10, 20, 40 and 80 mg/day decrease plasma adiponectin |
Randomized , single-blind , placebo-controlled , parallel study (Koh et al., 2015Koh KK, Oh PC, Sakuma I, Kim EY, Lee Y, Hayashi T, et al. Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. Int J Cardiol. 2015;199:126-131.) |
Korea |
Hypercholesterolemia |
203 |
2 months |
Each 51 patients receive either placebo, EZE 10 mg + SIM 10 mg (Vyto10), EZE 10 mg + SIM 20 mg (Vyto20) or SIM 20 mg alone once daily |
SIM 20 mg no different |
SIM 20 mg no different |
SIM 20 mg group not significant change insulin level |
SIM 20 mg group reduce the insulin sensitivity |
SIM 20 mg group significantly reduce plasma adiponectin level |
Randomized, single-blind, parallel intervention study (Bellia et al., 2010) |
Italy |
Patients with middle aged with T2DM and mild treated dyslipidemia |
29 |
4 weeks |
Patients receive either ROS 20 mg/day or SIM 20 mg/day |
Not measured |
No effect in both groups |
No effect in both groups |
No effect in both groups |
No effect in both groups |
Randomized, single-blind with two period (Bellia et al., 2012Bellia A, Rizza S, Lombardo MF, Donadel G, Fabiano R, Andreadi K, et al. Deterioration of glucose homeostasis in type 2 diabetic patients one year after beginning of statins therapy. Atherosclerosis. 2012;223(1):197-203.) |
Italy |
Well controlled T2DM patients |
27 |
12 months |
Patients receive either ROS 20 mg/day or SIM 20 mg/day for 6 months and switch the treatment for following next 6 months |
Both groups worsen A1C |
Both groups increase FBG |
No changes |
No effect in both groups |
Not significant increase |
Double blind randomized placebo-controlled study (Sen et a.l., 2002Sen K, Misra A, Kumar A, Pandey RM. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract. 2002;56(1):1-11.) |
India |
T1DM and T2DM with diabetic retinopathy |
50 |
180 days |
Patients receive either SIM 20 mg/day or placebo |
A1C in SIM group increase throughout the follow-up at 90 days and 180 days |
No significant changes in FBG |
No significant changes |
Not measured |
Not measured |
Randomized study (Tsutamoto et al., 2009) |
Japan |
Non-ischemic chronic heart failure |
71 |
2.2 ± 0.15 years |
Patients receive either SIM 5 mg/day (n = 35) or ROS 2.5 mg/day (n = 36) |
Slightly increase in SIM group & decrease in rosuvastatin group |
Not measured |
Not measured |
Not measured |
No changes in SIM group but increase in ROS group |
Randomized, case-control study (Krysiak, Okopien, 2013aKrysiak R, Okopien B. Effect of simvastatin on hemostasis in patients with isolated hypertriglyceridemia. Pharmacology. 2013a;92(3-4):187-190.) |
Polland |
Isolated hypertriglyceri-demia |
39 |
3 months |
Patients receive placebo or SIM 40 mg/day |
Not measured |
Both groups not significant |
Not measured |
Both groups not significant |
Not measured |
Double blind placebo controlled study (Farrer et al., 1994) |
United Kingdom |
Patients with T2DM dyslipidemia and mild hypertriglyceridemia |
70 |
6 months |
Patients randomized to receive placebo or SIM |
No significant changes |
No significant changes |
No significant changes |
Not measured |
Not measured |
Randomized, double-blind, placebo-controlled and two-period crossover study (Hwu et al., 1999Hwu C, Kwok C, Chen H, Shih K, Lee S, Hsiao L, et al. Lack of effect of simvastatin on insulin sensitivity in Type 2 diabetic patients with hypercholesterolaemia: results from a double-blind, randomized, placebo-controlled crossover study. Diabet Med. 1999;16(9):749-754.) |
Taiwan |
Patient T2DM with hypercholesterolemia |
19 |
6 months |
Patients receive either SIM 20 mg/day or placebo for 3 months and exchange the treatment for subsequent 3 months |
No effect in SIM group |
No effect in SIM group |
Not measured |
No effect in SIM group |
Not measured |
Randomized , double-blind, placebo-controlled, single center study (Szendroedi et al., 2009Szendroedi J, Anderwald C, Krssak M, Bayerle-Eder M, Esterbauer H, Pfeiler G, et al. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. Diabetes Care. 2009;32(2):209-214.) |
German |
Non-obese T2DM patients |
30 |
2 months |
Patients given placebo or SIM 80 mg/day |
No significant changes |
Not measured |
No significant changes |
No significant changes |
Not measured |
Randomized, case control study (Hydrie et al., 2007Hydrie MZI, Qasim R, Ahmadani MY, Miyan Z, Fawwad A, Basit A. Effect of simvastatin on insulin sensitivity in type 2 diabetic subjects. Pak J Medical Science. 2007;23(5):755.) |
Pakistan |
Patients with T2DM |
100 |
3 months |
50 patients receive SIM 40 mg/day as case and 50 patients as control group |
Not measured |
No significant changes |
No significant changes |
No significant changes |
Not measured |